ERBB2 and neoplasm: On the target cells, these include target antigen expression level and the primary resistance or general susceptibility of the target cells to CAR mediated effects for which a first indication of tumor control with acceptable toxicity was documented using GD2- (152) and HER2-specific CAR T cells (153).